About Us

Fostering Innovation and Excellence

The Cardiac Arrhythmia Network of Canada (CANet) brings together health care professionals, academia, government, industry, not-for-profit, and patients to support new ideas and ground-breaking research. Ultimately, CANet will provide innovative therapies and solutions to reduce premature deaths and suffering caused by heart rhythm disturbances.

Although heart rhythm care is a young clinical specialty, it has important roots in Canada. The first external cardiac pacemaker was developed in Toronto, and the first implantable heart recorder in London, Ontario. The Canadian heart rhythm research community, building on its past successes, is a world leader in this field.

CANet is committed to developing effective practical solutions that address unmet needs, and promote their use in personal, healthcare, and business applications. Our approach is to put the right tools in the right hands at the right time, to empower:

  • Patients to manage their own health
  • Caregivers to improve patient care at the bedside and in the community
  • Healthcare providers to give timely, effective, and efficient services

Patient engagement, knowledge translation, and commercialization of new therapies are central to CANet’s mission. A unique Patient Advisory Committee will consult and make recommendations about CANet’s governance, operations, and research programs.

CANet’s multidisciplinary and cross-sectoral approach is designed to foster innovation and excellence. This will enable CANet to come up with fresh ideas, set clear research priorities, build efficient and patient-centred healthcare solutions, and create competitive advantage for our biotechnology industry.

 

 

 

 

Our Vision: Access for all Canadians to early detection, effective prevention, efficient and timely treatment of arrhythmia and related conditions, through a transformed, patient-driven care model.

Our Targets

Research investments are carefully selected to achieve the targets (as set out in its application to the NCE) of:

  1. Over the next 10 year period, the network’s strategic clinical targets are:
    1. 10% drop in sudden cardiac death
    2. 20% drop in atrial fibrillation hospitalization and emergency department visits
    3. 30% drop in syncope hospitalization and emergency department visits
  2. Over the next 5 years, the network’s strategic business and capacity development targets are:
    1. Commercialization of 5-7 new technologies
    2. Launch of 30-40 new talents in public and private research
  3. Significantly improve the efficiency, effectiveness and accessibility of arrhythmia care delivery in Canada and the world.

   4. Generate $40 Million in research contributions from industry, government and not-for-profit sectors.

Critical considerations when evaluating proposals are the following:

  • Excellence of the research;
  • Development of highly qualified personnel;
  • Networking and partnership;
  • Knowledge & technology exchange & exploitation

NCE-RCE

Networks of Centres of Excellence

Canada’s global economic competitiveness depends on making new discoveries and transforming them into products, services and processes that improve the lives of Canadians. To meet this challenge, the Networks of Centres of Excellence (NCE) mobilizes Canada’s best research, development and entrepreneurial expertise and focuses it on specific issues and strategic areas.

The NCE networks are large-scale research centres that bring together partners from academia, government, industry and the not-for-profit sectors. The centres enable researchers to focus on excellence and innovation, to train highly qualified people, to create meaningful solutions to pressing problems, and to see their discoveries turned into marketable products and services.

Since its inception in 1989, the NCE has invested about $2 billion in research, commercialization and knowledge translation. Those investments have leveraged $1.5 billion in contributions from industry and other partners. The networks and centres have helped train more than 45,000 highly qualified personnel, and create 143 spin-off companies and 910 start-up companies.

CANet was formed in December 2014 through a $26.3 million grant over five years from the NCE.

Patient Engagement

Our goal is to ensure patient involvement throughout the research cycle through conception to execution, to implementation and to evaluation, leading to outcomes that will allow patients to co-manage their arrhythmia disorders and help produce both economic and social benefits for Canada.

Learn More

Highly Qualified Personnel

CHAT is the CANet HQP Association for Trainees. HQP are Highly Qualified Personnel in the field of arrhythmia research, and CANet strongly recognizes that the future lies in the development of the next generation of investigators, clinicians, and health care professionals.

Learn More